文献速递耳科与耳神经

偏头痛辅助药物治疗突发性感音神经性听力损失的疗效观察

Adjuvant Migraine Medications in the Treatment of Sudden Sensorineural Hearing Loss.
PubMed 文献 · Laryngoscope · 2020-04-03

结果显示联合治疗组在低频听力阈值和纯音平均听阈改善上显著优于对照组,且鼓室内注射次数更少。

要点

  • 联合偏头痛药物可显著改善低频听力阈值和纯音平均听阈。
  • 辅助偏头痛治疗减少鼓室内注射次数,降低操作相关风险。
  • 联合治疗组纯音平均听阈改善≥10 dB的比例显著更高。

核心结论

  • 在突发性感音神经性听力损失的多模式治疗中,口服和鼓室内类固醇联合偏头痛药物可能带来更好的低频 hearing 阈值和纯音平均听阈改善。
  • 辅助偏头痛治疗可减少鼓室内注射次数,从而降低操作相关风险和并发症。

研究设计与样本

  • 47例接受口服类固醇和鼓室内地塞米松注射单独治疗,46例接受相同类固醇治疗联合偏头痛生活方式改变及去甲替林和托吡酯组合治疗。

主要发现

  • 两组治疗后纯音平均听阈和250 Hz、8000 Hz听力阈值均有改善。
  • 与单独类固醇组相比,辅助偏头痛药物组在低频(250 Hz、500 Hz、1000 Hz)听力阈值改善显著更大。
  • 辅助偏头痛药物组纯音平均听阈改善更大(P = .01),且接受鼓室内注射次数更少(P = .04)。
  • 辅助偏头痛药物组36例(78%)观察到纯音平均听阈改善≥10 dB,对照组22例(46%)(P < .001)。

关键数值与推荐

  • 纯音平均听阈改善≥10 dB的比例:辅助偏头痛药物组78%(36/46),对照组46%(22/47),P < .001。
  • 纯音平均听阈改善组间比较P = .01,鼓室内注射次数比较P = .04。

临床怎么用

  • 对于突发性感音神经性听力损失患者,在口服和鼓室内类固醇治疗基础上,可考虑联合偏头痛药物(去甲替林和托吡酯)及生活方式改变以改善听力结局。
  • 联合偏头痛治疗可能减少鼓室内注射次数,从而降低操作相关风险和并发症。

局限性

  • 回顾性研究设计,证据等级为3级。
  • 未报告盲法或随机化信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/HYPOTHESIS: To examine the hearing outcomes of patients with sudden sensorineural hearing loss (SSNHL) treated with oral and intratympanic (IT) steroid only or a combination of steroid and migraine treatment. Our hypothesis was that adjuvant migraine medications may improve outcomes in SSNHL. METHODS: A retrospective chart review at a tertiary otology center was conducted to identify patients with SSNHL who received oral steroid and IT dexamethasone injection(s) with or without migraine medications (a combination of nortriptyline and topiramate). RESULTS: A total of 47 patients received oral steroid and IT dexamethasone injection(s) only, and 46 patients received oral steroid and IT dexamethasone injection(s) as well as migraine lifestyle changes plus a combination of nortriptyline and topiramate. There were no significant differences in demographics and baseline audiometric data between the two groups. Both groups demonstrated improvements in pure tone average (PTA) and hearing thresholds at 250 Hz and 8000 Hz posttreatment. However, compared to steroid-only group, the adjuvant migraine medications group had significantly greater improvements in hearing thresholds at the lower frequencies (250 Hz, 500 Hz, 1000 Hz). Patients in the latter cohort also had greater improvement in PTA (P = .01) and received fewer IT injections (P = .04) PTA improvement of ≥ 10 dB was observed in 36 patients (78%) in the adjuvant migraine medications group and 22 patients (46%) in the control group (P < .001). CONCLUSION: In multimodal treatment of SSNHL, supplementing oral and IT steroid with migraine medications may result in greater improvements in lower frequency hearing thresholds and PTA. Furthermore, adjuvant migraine treatment can lead to decrease in number of IT injections, thus reducing procedure-related risks and complications. LEVEL OF EVIDENCE: 3 Laryngoscope, 131:E283-E288, 2021.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Abouzari M, Goshtasbi K, Chua JT, et al. Adjuvant Migraine Medications in the Treatment of Sudden Sensorineural Hearing Loss. Laryngoscope. 2020. PMID: 32243585. doi:10.1002/lary.28618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。